OBJECTIVES: To assess the impact of the introduction of newer LARC methods on LARC use relative to all contraceptive users. METHODS: Using a US insurance claims database (01/1999-03/2014), we studied women using LARC or short acting reversible contraceptive (SARC) methods. The proportion of women using LARC relative to all contraceptives (LARC+SARC) was reported yearly. Four time periods corresponding with the approval of a new LARC method, that is, Jan­2001 (new intrauterine device [IUD]), Jul­2006 (new implant), and Jan­2013 (new IUD), were identified. Generalized estimating equation models were utilized to identify the impact of time periods and patient characteristics on the use of LARC over SARC methods.  RESULTS: A total of 1,040,978 women met inclusion criteria. LARC use increased yearly from 0.6% (1999) to 16.6% (2013) among all contraceptive users. Time periods associated with the introduction of a newer LARC method were significant predictors of LARC use; women in 2006‑2012 and 2013‑2014 were respectively 3.7-fold (95%CI: 3.57-3.74) and 6.6-fold (95%CI: 6.43-6.80) more likely to use LARC over SARC relative to women in 2001‑2006. The increase in LARC use was especially pronounced in young women. Compared to women aged 18 to 24 in 2001‑2006, women aged 18 to 24 in 2006‑2012 and in 2013‑2014 were respectively 6.4-fold (95%CI: 5.91-6.86) and 14.7-fold (95%CI: 13.59-15.89) more likely to use LARC over SARC method. CONCLUSIONS: This broadly representative commercial claim-based study showed that the proportion of women using LARC increased over time and that the introduction of newer LARC methods corresponded with significant increases in overall LARC use.